 | |
| Clinical data | |
|---|---|
| Other names | Desmethylenzalutamide; Norenzalutamide |
| Drug class | Nonsteroidal antiandrogen |
| Pharmacokinetic data | |
| Protein binding | 95%[1] |
| Eliminationhalf-life | 7.8 days[2][1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C20H14F4N4O2S |
| Molar mass | 450.41 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
N-Desmethylenzalutamide is anonsteroidal antiandrogen (NSAA) and the majormetabolite ofenzalutamide, an NSAA which is used as ahormonal antineoplastic agent in the treatment ofmetastaticprostate cancer.[3][4][2] It has similar activity to that of enzalutamide and, with enzalutamide therapy, circulates at similar concentrations to those of enzalutamide atsteady state.[3][4][2]N-Desmethylenzalutamide is formed from enzalutamide in theliver by thecytochrome P450enzymesCYP2C8 andCYP3A4.[4] It has a longerterminal half-life than enzalutamide (7.8 days versus 5.8 days).[2]
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
